Fig. 1

MYPT1 is downregulated by miR-30b in ovarian tumors and reduces overall survival in ovarian cancer patients. a MYPT1 expression in the GSE40595 and GSE38666 ovarian cancer patient databases. Box plots showing the expression levels of MYPT1 in ovarian tumor tissue (blue) or non-tumor tissue (red) patients. Data were analyzed by comparing the tumor versus the normal samples using Student’s t-test. *, P < 0.05. b Representative images of MYPT1 immunostaining in ovarian cancer and non-tumoral ovary samples. c Kaplan-Meier plots showing overall survival of patients with high (red) or low (blue) MYPT1 expression levels in two databases with survival data (Duke OC cohort and GSE14764). Data were analyzed with the log-rank test, and the associated P-values are shown in the graphs. d Correlation of the expression levels of miRNAs and MYPT1 in the TCGA ovarian cancer database. Data were analyzed using Pearson’s R correlation. *, P < 0.05; **, P < 0.01; ***, P < 0.001. e Left, putative miR-30b binding site in the 3′ -UTR of the MYPT1 gene. Right, luciferase activity assay of the 3′-UTR of MYPT1 in HEK293 cells expressing or not (mirNC) miR-30b. f MYPT1 expression levels measured by RT-qPCR in ES-2, SKOV3 or OVCAR8 ovarian cancer cell lines expressing miR-30b or EV. g Kaplan-Meier plots showing overall survival of patients with high (red) or low (blue) MYPT1 expression levels (left), high (red) or low (blue) miR-30b expression levels (middle) or their combination (right) in the TCGA ovarian cancer database. Data were analyzed with the log-rank test, and the associated P-values are shown in the graphs